🇺🇸 FDA
Patent

US 7897355

Gene expressed in prostate cancer and methods of use

granted A61KA61K39/00A61P

Quick answer

US patent 7897355 (Gene expressed in prostate cancer and methods of use) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Feb 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Mar 01 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K39/00, A61P, A61P35/00